January 2022 FDA Recall Proctofoam by Mylan Pharmaceuticals Inc
D-0452-2022 - cGMP deficiencies

This Class II drug recall was voluntarily initiated by Mylan Pharmaceuticals Inc on January 21, 2022 for the product Proctofoam. The FDA reported the reason for recall as cgmp deficiencies. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0452-2022

Reason for Recall
cGMP deficiencies
Initiated
01-21-2022
Reported
02-02-2022
Quantity
233,199/10 g aerosol containers

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Mylan Pharmaceuticals Inc
Recalled product was distributed nationwide within the United States.
Proctofoam HC (hydrocortisone acetate 1% and pramoxine hydrochloride 1%) topical aerosol, 10 g aerosol containers, Rx Only, Distributed by Meda Pharmaceuticals Inc, Somerset, New Jersey 08873-1120, NDC 0037-6822-10.

Batch or Lot Expiration Information

Lot# : 32925, Exp. date May 2023, 33010, Exp. date June 2023; 33119, 33123, Exp. date August 2023

Affected Packages Involved in this Recall